Endogenous Granulocyte Macrophage Colony Stimulating Factor (GMCSF) is released in rheumatoid arthritis patients, who are largely protected from Alzheimerââ¬â¢s disease (AD). Introducing exogenous GMCSF into an AD mouse model reduced amyloid deposition by 55% and restored normal cognition. No published studies have examined exogenous GMCSF and cognitive functioning in humans. Amyloid reduction could result from induced phagocytosis by activated microglia/infiltrating macrophages and neutrophils with macrophages having greater phagocytic ability by induction of MMP-9 from infiltrating macrophages/neutrophils by reduced deposition, or by a combination of these mechanisms. Amyloid reduction could result from induced phagocytosis by activated microglia/infiltrating macrophages and neutrophils with macrophages having greater phagocytic ability by induction of MMP-9 from infiltrating macrophages/neutrophils by reduced deposition, or by a combination of these mechanisms.
Heather SL Jim, Granulocyte Macrophage Colony Stimulating Factor Treatment is
Associated with Improved Cognition in Cancer Patients
Last date updated on September, 2024